Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.72 |
| ▸ | TTR | P02766 | 3/20 | 0.68 |
| ▸ | MIF | P14174 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | TYR | P14679 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265141 | 1.00 | BACE1 (0.72) | BACE1TTRMIFCA1CA2 | |
| SCHEMBL1646653 | 0.84 | BACE1 (1.00) | BACE1TTRAKR1B10AKR1B1MAOB | |
| SCHEMBL1646654 | 0.84 | BACE1 (1.00) | BACE1TTRAKR1B10AKR1B1MAOB | |
| SCHEMBL165227 | 0.83 | MAPT (0.65) | PKMMAPTMEN1KMT2ANPC1 | |
| SCHEMBL29419102 | 0.83 | MAPT (0.65) | PKMMAPTMEN1KMT2ANPC1 | |
| SCHEMBL481451 | 0.83 | MAPT (0.65) | PKMMAPTMEN1KMT2ANPC1 | |
| SCHEMBL28068228 | 0.82 | TYR (0.72) | BACE1TTRPKMTYRDPP4 | |
| SCHEMBL11459860 | 0.81 | MAPT (0.63) | PKMMAPTMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL6822024 | 0.81 | MAPT (0.63) | PKMMAPTMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL27093058 | 0.81 | MAPT (0.63) | PKMMAPTMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-2757093-A1 | GUANIDINOBENZOIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-7053071-B2 | For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells | THE BURNHAM INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| EP-1456165-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | The Burnham Institute (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2003-09-18 | — | — | US | disclosed |
| WO-2003048101-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | THE BURNHAM INSTITUTE (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0155652-B2 | PHOTOPOLYMERIZABLE MIXTURE AND RECORDING MATERIAL PRODUCED FROM IT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-10 | — | — | EP | disclosed |
| EP-0155652-B1 | PHOTOPOLYMERIZABLE MIXTURE AND RECORDING MATERIAL PRODUCED FROM IT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | BACE1 1069/4885TTR 362/4885MIF 655/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | BACE1 4022/4885TTR 4688/4885MIF 1677/4885 |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | MCL1, BAD, BCL2 | BACE1 3709/4885TTR 4544/4885MIF 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.